HUMA · Humacyte Inc
United States · RS rating 4 · As of 2026-10-14
| Price | 0.35 USD |
|---|---|
| 1-day change | -1.3% |
| RS rating (overall / 1M / 3M / 12M) | 4 / 4 / 6 / 6 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 18 / 15 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -77.8% |
| Sales growth Q/Q | -38.0% |
| Distance from 52-week high | +80.4% |
| Market cap (USD) | $157.2M |